The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis

• Published in: Medicine (Baltimore) Vol. 98; no. 44; p. e17773
• Main Authors: Wang, Sumei, Zhang, Jiandong, Liu, Shuye, Zhang, Jinjuan
• Format: Journal Article
• Language: English
• Published: United States the Author(s). Published by Wolters Kluwer Health, Inc 01-11-2019; Wolters Kluwer Health
• Subjects: Aged; Bone Neoplasms - mortality; Bone Neoplasms - secondary; Brain Neoplasms - mortality; Brain Neoplasms - secondary; Chi-Square Distribution; Clinical Trial/Experimental Study; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms - mortality; Liver Neoplasms - secondary; Lung Neoplasms - mortality; Lung Neoplasms - secondary; Male; Middle Aged; Multivariate Analysis; Neuroendocrine Tumors - mortality; Neuroendocrine Tumors - secondary; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Prognosis; SEER Program; Survival Rate
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000017773

To evaluate the prognostic value of pancreatic neuroendocrine tumors (pNETs) with different metastatic patterns.
Data of pNETs cases were extracted from the Surveillance, Epidemiology, and End Result (SEER) database. They were classified according to the different metastatic patterns. We utilized chi-square test to compare the clinical and metastasis characteristics among different groups. We used Kaplan-Meier analysis and log-rank testing for survival comparisons. Adjusted HRs with 95% CIs was calculated using Cox regression model to estimate prognostic factors. P < .05 was considered statistically significant.
Among the 3909 patients, liver is the most metastatic organ, and isolated brain metastasis is the least common. At the same time, many patients have had multiple metastases. We studied the overall survival (OS) and cancer-specific survival (CCS) of the groups. OS: Non-organ metastasis: 5-year OS = 77.1%; Bone metastasis: median survival time (MST) = 56 m, 5-year OS = 42.7%; Liver metastasis: MST = 24 m, 5-year OS = 25.5%; Lung metastasis: MST = 14 m, 5-year OS = 33.7%; multiple metastases: MST = 7m, 5-year OS = 12.0%. CCS: Non-organ metastasis: 5-year OS = 84.2%; Bone metastasis: 5-year OS = 52.5%; Liver metastasis: MST = 27 m, 5-year OS = 28.6%; Lung metastasis: MST = 49 m, 5-year OS = 40.1%; multiple metastases: MST = 8 m, 5-year OS = 14.5%. In addition, the results showed that there were all statistical significances between the surgery and the no surgery group (all, P < .001). Multivariate analysis revealed that brain metastasis, multiple metastases, age over 60 years, unmarried, grade III/IV, regional/distant and no surgery were independently associated with decreased OS and CCS.
pNETs patients without organ metastasis had the best survival outcomes, while multiple had the worst outcomes. There were no significant differences in bone metastasis, liver metastasis and lung metastasis. Surgery was still an option for patients with metastasis.